SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Utilising unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide

Preventing disease by triggering the body’s own immune system is one of medical science’s greatest achievements. Only access to clean drinking water is more important to human health. Yet we still lack vaccines for dozens of viral, bacterial and parasitic infectious diseases, as well as therapeutic vaccines to advance the treatment of cancer.  

SpyBiotech came into being to change that. Our pioneering technology, the proprietary protein superglue SpyTag/SpyCatcher, enables us to develop safe and highly effective vaccines with greater ease and speed. Our ambition is to leverage the benefits of our unique platform to address major human health challenges around the world.

Our Pipeline

We are developing novel vaccines against two widespread diseases with life-threatening implications, particularly for babies and children, that currently lack effective treatment or prevention. One of these is human cytomegalovirus (CMV).

We have initiated GMP manufacturing of our CMV candidate.

Follow the journey of our protein superglue

Our Story